SEC v. John Paul Waymack (2018)

Status unknown

✓ Checked against the primary document on October 3, 2026. The library's summary, tags and figures for this record were compared with the regulator's own document by an AI model (Claude) following written instructions, with sampled and disputed records read a second time. No lawyer has reviewed them. A checked record can still contain errors, and checked does not mean endorsed. See how we check records or report a correction.

Report an error in this record (sec-john-paul-waymack-2018) by email

In September 2018 the SEC filed a subpoena enforcement action in Washington to compel Kitov Pharmaceuticals chairman John Paul Waymack to produce documents and testify for a request from the Israel Securities Authority. The filing charges no insider trading, and no outcome is recorded.

The record

What was ordered

Civil penalty

—

Disgorgement

—

Prejudgment interest

—

Total relief

—

Alleged gain

—

A dash means the release did not state a figure we could extract, not that the figure is zero. Penalty and disgorgement are stored separately so aggregates across the library do not double-count the same dollars.

What is alleged to have happened

The SEC said it was gathering information for the Israel Securities Authority, which was investigating possible insider trading and misstatements in Kitov's disclosures. Waymack had refused to comply with a June 2017 subpoena. The action seeks an order enforcing the subpoena; it alleges no violation by Waymack, so the insider-trading tag has been removed.

Timeline

1. 2018-09-18 Litigation release published

Primary documents

Everything on this page derives from the documents below. Where our summary and the primary document disagree, the primary document is right.

• SEC litigation release

The linked release is a work of the United States government and is not subject to copyright. Our summary and narrative above are our own writing.

Record added September 10, 2026. submit a correction.